Author Question: How long should each phase be in a changing criterion design? A. Phases should be long enough to ... (Read 109 times)

NguyenJ

  • Hero Member
  • *****
  • Posts: 516
How long should each phase be in a changing criterion design?
 
  A. Phases should be long enough to allow stable responding
   B. The length of the phase should be varied if possible
   C. Phases should be brief enough to see a positive response
   D. Both A and B

Question 2

What is the chief advantage of an A-B-A-B design over a simpler A-B design, assuming the independent and dependent variables are the same as well as the subject, setting, etc.?
 
  What will be an ideal response?



yifu223

  • Sr. Member
  • ****
  • Posts: 302
Answer to Question 1

D

Answer to Question 2

An A-B-A-B design offers a replication of the original intervention effect found in a simpler A-B design. That is, the researcher is able to demonstrate the functional relationship between the independent and dependent variable twice (A1-B1-A2-B2) versus only the once in the A-B design.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
 

Did you know?

Patients who cannot swallow may receive nutrition via a parenteral route—usually, a catheter is inserted through the chest into a large vein going into the heart.

Did you know?

When intravenous medications are involved in adverse drug events, their harmful effects may occur more rapidly, and be more severe than errors with oral medications. This is due to the direct administration into the bloodstream.

Did you know?

Eating food that has been cooked with poppy seeds may cause you to fail a drug screening test, because the seeds contain enough opiate alkaloids to register as a positive.

Did you know?

In 1886, William Bates reported on the discovery of a substance produced by the adrenal gland that turned out to be epinephrine (adrenaline). In 1904, this drug was first artificially synthesized by Friedrich Stolz.

Did you know?

The first monoclonal antibodies were made exclusively from mouse cells. Some are now fully human, which means they are likely to be safer and may be more effective than older monoclonal antibodies.

For a complete list of videos, visit our video library